Following these initial statistical analyses, two SATB2-groups were formed: CRCs that showed an SATB2 expression above the 20th percentile (>70% tumour cells; n = 808, 78%) were categorised as SATB2-high, CRC on/below the 20th percentile (range:0–70% of tumour cells; n = 231, 22%) were categorised as SATB2-low/absent. The gene discussed is SATB2; the disease is colorectal carcinoma.